

Annual Report **Rīpoata-ā-Tau**



2025 - 2026

On the cover: Bronwyn



Bronwyn is an incredible woman living with high-grade serous ovarian cancer (HGSOC) whose strength and determination always inspire us. Rather than letting her diagnosis define her, she has embraced the huge challenge of taking on the Coast to Coast to show herself what she's capable of, honour her dear friend Wendy, who also had HGSOC, and raise funds for other women affected by ovarian cancer.

We are also grateful to Bronwyn for sharing her story as part of our State of Ovarian Cancer in Aotearoa report. Her courage and generosity are helping raise awareness, drive change, and create a better future for women diagnosed with ovarian cancer.



**Watch Bronwyn
share her story**



ovariancancerfoundation.org.nz



office@ocfnz.org.nz



/ovariancancerfoundationnz



/ovariancancerfoundationnz



/Ovarian Cancer Foundation New Zealand

A note on terms used:

- ▶ Unless otherwise specified, "ovarian cancer" includes cancer of the fallopian tubes, peritoneum and ovaries.
- ▶ Low-grade serous ovarian cancer may also be referred to in this report as low-grade serous carcinoma or cancer, LGSOC and LGSC.
- ▶ The Ovarian Cancer Foundation may be referred to as OCFNZ.



Launched our two lived experience advisory committees, one made up of women facing ovarian cancer, and one made up of family members of women who have faced a diagnosis or passed away from ovarian cancer

Continued to Show Up for Ovarian Cancer during Ovarian Cancer Awareness Month, raising over \$40,000 to support Kiwi women facing ovarian cancer



Highlights

Launched the State of Ovarian Cancer in Aotearoa Report at Parliament calling for eight key asks to improve outcomes for women and whānau facing ovarian cancer

Hosted Frocktober for the first time, raising over \$155,000 with net proceeds dedicated to ovarian cancer research in Aotearoa



Hosted our first-ever fundraising event, the Auckland Long Lunch which raised over \$90,000 for ovarian cancer research

175 support sessions were delivered to women across peer-support, funded one-on-one counselling and funded physiotherapy and rehabilitation

We continue to be New Zealand's largest funder of ovarian cancer research with over \$150,000 invested in research this year

Contents Ngā kōrero

Highlights	2
Our vision and mission	4
Message from General Manager	5
Our team	7
Advocacy	9
Costs	11
Frocktober	13
Research	15
Long Lunch	17
Awareness	19
Support	21
Show Up	23
LGSOC	25
Advisory committees	29
Message from Founder and Chair	31
Thank you	33
Financial report	35



Our vision Tō mātou whainganga

Every woman has the chance
to live the life she wants, free
from ovarian cancer.

Our mission Tō mātou kaupapa

To improve ovarian cancer care
today while funding
transformational research to
find tomorrow's cure.



A message from our General Manager

He whakairo nā tō mātou Tumuaki

Tena koe and a warm welcome to our annual report.

I am experiencing a huge sense of privilege to be reflecting on my first year leading the team at the Ovarian Cancer Foundation New Zealand, after five years serving as a trustee.

I would like to take a moment to acknowledge two remarkable women whose leadership has helped shape this year. Firstly, my sincere thanks to outgoing General Manager Whitney Gernhoefer, whose passion, commitment and hard work have left a lasting mark on OCFNZ and the women and whānau we serve. I would also like to thank OCFNZ Chair Alana Allan, who stepped into an interim leadership role while I was being recruited. Alana led with generosity, care and determination, ensuring OCFNZ continued to move forward with purpose during a period of transition. I am grateful for the time, energy and leadership she gave to our community.

While the year has been busy and we have introduced new programmes of work, new fundraising initiatives and undertook a new report into the state of ovarian cancer in Aotearoa, we continue to focus our work across four key priority areas (research, advocacy, support and awareness) dedicated to changing the ovarian cancer space in Aotearoa.

Growing our impact

Gathering evidence

We have conducted three national surveys to gather evidence of the state of ovarian cancer in New Zealand; we surveyed women with lived experience of ovarian cancer, GPs and health practitioners, and the New Zealand public.

The survey outcomes reinforced our expectations about the low levels of awareness of ovarian cancer symptoms, the concerns about diagnosis and treatment pathways and the range of challenges in the health care system that are not serving women well.

Driving change through evidence and advocacy

Releasing the State of Ovarian Cancer in Aotearoa report at Parliament in February saw women and family members with lived experience speaking directly to decisionmakers and changemakers in the broader community.

The report included 8 'asks' that set out clearly what needs to change, grounded in evidence, expert insight, and the voices of women and whānau with lived experience of ovarian cancer.

We remain steadfast in our commitment to gain traction on the recommendations and are actively pursuing meetings and discussions with MPs, Ministers and public officials and included a presentation to the Health Select Committee.

Keeping women and their families front and centre

We have established two lived experience advisory groups that are informing our work and providing guidance and input into our strategic direction and day to day focus. These voices play a critical role in our focus at both governance and operational levels.

Holding up research as key

We engaged in our first fashionable campaign, Frocktober! Inviting people to dress up across the month with all funds going to research here in New Zealand. We also held our first ever long lunch in Auckland, another new fundraising initiative for us with a focus on raising funds for research.

As a result we are this year able to support two significant research grants, two international travel grants and four professional development grants.

Providing trusted support and connection

We continue to offer one-on-one counselling services with the addition of Rongoa Māori services this year. Our online peer-support groups for women continue as do our funded rehabilitation services.

Keeping ovarian cancer in the public conversation

We continue to run public awareness campaigns and have undertaken a growing number of speaking engagements, visited workplaces talking with staff and partnered with some outstanding community organisations who share a commitment to this work.

As our Founder Jane Ludemann has said so eloquently "these steps matter but they are just the start of what is needed to address long-standing inequities."

It is an honour to write this first report.
Ngā mihi nui

Liz Pennington



Our team Tā mātou rōpū



Liz Pennington
General Manager
Tumuaki



Holly Townsend
Engagement and
Support Coordinator
Kaiwhakahaere Hononga,
Tautoko hoki



Kim Marsh
Service Delivery and
Finance Administrator
Kaiwhakahaere ngā mahi
tautoko me ngā pūtea hoki



Alison Black
Grants Officer
Kaiwhakahaere Kohinga



Lisa Almand
Support Facilitator
Kaiwhakarite ngā Rōpū Tautoko



Kelly Conway
Policy Advisor
Kaiwhakarite Tikanga Whakaaro

Our Board Ō mātou tāngata



Alana Allan
Chairperson
Tiamana Poari



Jane Ludemann
Founder
Tō mātou Kaiwhakapoupoua



Alicia Didsbury
Trustee
Kaitiaki



Ben Russell
Trustee
Kaitiaki



Madison Chamberlain
Trustee
Kaitiaki



Linda Leonard
Trustee
Kaitiaki



Malcolm MacLeod
Trustee
Kaitiaki

Growing our team, strengthening our impact

This has been an incredible year of growth for the Ovarian Cancer Foundation New Zealand. We are thrilled to welcome Linda Leonard and Malcolm MacLeod to the OCFNZ Board, both have already made huge contributions. Malcolm is our Treasurer and a member of our Whānau Lived Experience Advisory Committee. He also spearheaded our successful Auckland Long Lunch. Linda has brought a focus on corporate partnerships and has played a key role in our awareness activities, including attending community events and launching our first-ever Street Appeal during Ovarian Cancer Awareness Month.

Operationally, we have welcomed Kim Marsh and Kelly Conway to the team in newly created roles that increase our capacity and strengthen our support for the community. We are also delighted to welcome Liz Pennington as our new General Manager. Liz stepped off the OCFNZ

Board to take up this role, bringing with her extensive not-for-profit leadership experience and a strong commitment to women-focused advocacy and support. She has already made an incredible impact and we are so lucky to have her leading the team into this next phase of growth.

Growing our team has been an important part of growing our impact. While this has increased our administration costs, it reflects a deliberate investment in building the capacity needed to strengthen our support, advocacy, awareness and research, ensuring we remain a sustainable organisation for the future. This increased capability is already showing results in us delivering two new revenue streams, the Long Lunch and Frocktober, launching our first State of Ovarian Cancer report, significantly increasing research investment and the number of women supported year-on-year.



Ele Ludemann

Our patron - Tō mātou Kaiwhakarangatira

We are delighted to welcome Ele Ludemann as the first Patron of the Ovarian Cancer Foundation New Zealand. Ele has been part of the OCFNZ story since the very beginning, joining the Board in 2018 when her daughter Jane founded the organisation. Her passion, generosity, and unwavering commitment to improving outcomes for women with

ovarian cancer have made a lasting impact, and we can think of no one better suited to this role.

“Ele’s dedication, generosity, and unwavering support have helped shape OCFNZ from the very beginning. We’re honoured to welcome her as our Patron.”

- Liz Pennington, OCFNZ General Manager

Advocacy Whakakōkiri

State of Ovarian Cancer in Aotearoa

He kōrero mo te ahuatanga o te mate pukupuku kākano-ā-kopu ki Aotearoa

In February 2026 OCFNZ launched a new report that confronts one of New Zealand's most serious health crises. The toll ovarian cancer takes is devastating with an average of 306 new diagnoses each year, and the death of one woman every 48 hours.

This report delves into insights shared by women facing ovarian cancer, their families, Kiwi GPs, the New Zealand

public, our expert researchers and advocates, and the stats and facts available to us.

Opening and closing with the voices of women facing ovarian cancer, the report shines a light on what's going well, where change is needed, and what we're asking for to make that change happen.

Our asks

- ▶ Reduce the incidence of emergency diagnosis by:
 - improving awareness and education of the NZ public and primary health care providers, and
 - improving health pathways to support better access to ultrasounds.
- ▶ Address data gaps and make accurate, real-time data more accessible across the health system by introducing an ovarian cancer registry
- ▶ Identify people at higher genetic risk before they get ovarian cancer
- ▶ Address gynae-oncology specialist shortages to improve ovarian cancer care
- ▶ Prioritise ovarian cancer clinical trials to progress research and give Kiwi wāhine better access to cutting edge treatments
- ▶ Increase funding and focus on ovarian cancer by the Health Research Council of New Zealand
- ▶ Inclusion for people with lived experience, their whānau and patient advocacy groups in service design, policy and research
- ▶ Improve medicines access and investment to close survival rates between New Zealand and other countries.

What we found:

The five-year survival rate of ovarian cancer is just **43%**

30% of women diagnosed will die within one year



Māori and Pacifica wahine face the **highest rates** of emergency diagnosis




GPs cite access to ultrasound as a **key barrier** to timely diagnosis

50% of women

diagnosed with ovarian cancer **visited their doctor three or more times** before they were offered testing



Almost half of women are diagnosed through the emergency department, this leads to poorer outcomes, with one year mortality increasing from **17% to 42%**



One out of five women had to wait **over a year** from their first doctors appointment to get diagnosed

By combining lived experience with evidence, the report establishes a clear focus for OCFNZ's advocacy work and reinforces the urgent issues that women with ovarian cancer have long told us need attention.




Read the full report

Breakdown of costs and how each dollar is used

Ā mātou whakahaere ia taara

A portion of our salaries are generously covered by a major donor and grant funding. While our investment in our team has increased as we have grown, this support helped keep our administration costs lower than they would otherwise be, allowing us to build a stronger, more sustainable organisation while maximising the funds directed to supporting women and whānau.



Frocktober

Kākahu-mo-Whinga-a-nuku

In October 2025, OCFNZ officially brought Frocktober to Aotearoa for the very first time and wow, did New Zealand show up in style.

Inspired by the work of Ovarian Cancer Research Foundation and the fabulous grassroots fundraising already popping up around the country, we saw an opportunity to bring Kiwi “frockers” together for one shared mission: raising vital funds for ovarian cancer research while having a whole lot of fun along the way.

From morning dips in frocks to frocking up at the gym, Kiwis embraced Frocktober with creativity, style, and heart. Across the month, 222 incredible fundraisers and 1,964 generous donors helped raise an amazing \$155,000 for ovarian cancer research.

Supporters took part in all kinds of ways, wearing frocks every day through October, hosting events, rallying workplaces, gathering friends and whānau, and turning everyday moments into opportunities to spark conversations about ovarian cancer. Together, the campaign reached audiences right across Aotearoa,

helping spread awareness of ovarian cancer and the urgent need for more research.

Some supporters had been “frocking up” long before the official campaign arrived. Anita, Ashlyn, and Sheena from Twizel, three generations of mums and daughters, have proudly championed the cause since 2021. Their energy, commitment, and glamour captured exactly what Frocktober is all about!

The campaign also received an incredible boost through matched giving from Rotary Club of Oamaru. Their support helped us raise over \$27,000 in just one day.

Frocktober 2025 showed the power of people coming together behind a shared cause. It was fun, fabulous, and deeply meaningful. Most importantly, it helped strengthen our ability to invest in life-changing ovarian cancer research and support better outcomes for women across Aotearoa.

To every person who wore a frock, hosted an event, donated, shared a social media post, or encouraged a friend to get involved, thank you. You helped make our first official Frocktober in New Zealand a **frocking fantastic success**.



Research Whakarangahaua

Research has always been at the core of what we do. It is the pathway to our vision: every woman having the chance to live the life she wants, free from ovarian cancer.

This year, we hosted two fundraising events dedicated to investing in ovarian cancer research in Aotearoa. We were blown away by their success, and deeply encouraged by the incredible support from our community. It reinforced just how strongly our community believes in the importance of advancing ovarian cancer research to improve outcomes for women across New Zealand.

While the funds raised will be primarily spent next year, the success of these fundraising initiatives did give us the confidence

to invest more in research this year than we had previously planned. We intended to fund one major grant, one travel grant and participation in a clinical trial. But we were able to significantly expand that commitment to include

- An additional travel grant
- Funding Associate Professor Heather Cunliffe's LGSOC research
- Funding for an Honours research project
- Additional support for past major grant recipient Aaron Stevens to continue his work
- Two new professional development grants

Major grant

Dr Qi Chen, Associate Professor, Department of Obstetrics and Gynaecology, University of Auckland. Dr Chen is studying opportunities to inhibit ovarian tumour growth by investigating how placental extracellular vesicles can act as an immune modulator. This research investigates ways to stop the growth of ovarian tumours by studying how placental extracellular vesicles (tiny, bubble-like structures that can carry messages between cells) can alter the body's immune response.



Dr Qi Chen
University of Auckland

MoST clinical trial

We committed to funding spaces for 10 women with rare ovarian cancers to access the groundbreaking Molecular Screening and Therapeutics (MoST) trial. We're proud to provide this support to Auckland City Hospital oncologist Dr Michelle Wilson and her team, to help women access the trial and empower clinicians to detect potentially life-changing, targeted treatments and contribute to vital research that will improve care for others.

Travel grants

Our travel grant provides funding so early career researchers can visit an international laboratory. This visit will facilitate stronger global cooperation, and expose researchers to new ideas and techniques that they can bring back to Aotearoa.

Rosa Latton and Katie Walker, both of the University of Otago, will be travelling to the UK and Australia respectively to soak up knowledge from world-leading teams and further their own research in Aotearoa.



Rosa Latton
University of Otago



Katie Walker
University of Otago

Zonta Club of Oamaru

The incredible Zonta Club of Oamaru hosted a fantastic lunch event in June, featuring a South American BBQ, auction, raffle, and guest speaker Peter Williams, who shared his experience of supporting his wife through ovarian cancer and the loss of her life to the disease.

The dedicated group raised more than \$20,000 through this impactful event. An effort that will have a huge impact on wāhine facing ovarian cancer.



Long Lunch Tina Hākari

The Long Lunch was an incredible event for us in 2025, born from one person's determination to make a difference.

Malcolm MacLeod reached out to us following his wife's ovarian cancer diagnosis. He had a desire to do something meaningful to support all women facing ovarian cancer, his simple idea grew into an afternoon that exceeded all expectations, filled with generosity, connection, and an incredible sense of community.

His idea was the inaugural OCFNZ Long Lunch. An opportunity to learn about the realities women with ovarian cancer face, and to do something about it.

Over 170 people turned up ready to make a difference. There were tears, laughter, and some very competitive bidding, with MC Mary Lambie and auctioneer Shane Cortese keeping the energy high from start to finish.

One of the most memorable moments came when Erin Bassett, a woman living with low-grade serous ovarian cancer, received a standing ovation after sharing her story during a panel discussion with researcher Dr Alicia Didsbury and medical oncologist Dr Rosalie Stevens. Erin's honesty and courage left many in the room visibly moved as she spoke about the years of misdiagnoses, the devastating impact of treatment that left her in menopause and infertile, and the ongoing uncertainty of living with a cancer that has a high recurrence rate.

The event also benefited from the generous support of Mark Scott and his family whose late wife Coral had crafted a gin aptly named Coral Gin. Mark and his son Daniel led those gathered in a toast. The generosity in the room was extraordinary, with some auction items selling for up to \$13,000. In total, the event raised over \$90,000 through live and silent auctions and donations, an incredible result that gave us the confidence to increase our research spend in 2025 (refer to research pages) and will see us invest more than ever next year.

Thank you to everyone who attended, and a special thanks to volunteer Stella Coleman, OCFNZ Chair Alana Allan and Malcolm MacLeod, who has since become an OCFNZ Trustee for your tireless efforts to bring this event to life.



“ It was such an honour and privilege to be involved in the OCFNZ Long Lunch and share my story. It was one of the most powerful moments of my life. To have the opportunity to speak out, raise awareness, and fight for more research funding felt like turning pain into purpose, for myself, and for every woman impacted by this disease. - Erin Bassett, speaker ”



Awareness Whakamōhio

Raising awareness through lived experience. Awareness is about more than sharing information. It is about helping people understand the realities of ovarian cancer, recognise symptoms, and appreciate the huge impact ovarian cancer can have on every aspect of a woman's life.

Engaging with frontline healthcare professionals

In August, Founder Jane and Trustee Linda attended the South General Practice and Medical Exhibition Conference, connecting with frontline healthcare professionals from across New Zealand. The conference provided an opportunity to share the experiences of women with ovarian cancer while gaining valuable insight into the challenges clinicians face in supporting timely diagnosis.

Many practitioners expressed frustration with barriers to accessing publicly funded ultrasounds, describing difficulties navigating referral pathways and securing timely investigations for patients with ongoing symptoms. Conversations also highlighted varying levels of understanding around the role of CA-125 testing, reinforcing the importance of continued education and awareness within primary care. The conference was also an opportunity to invite healthcare professionals to contribute their perspectives to our State of Ovarian Cancer in Aotearoa report, helping ensure the experiences of both patients and clinicians are reflected in our advocacy work.

Bringing lived experience to future health professionals

Our founder Jane also spoke as part of the Survivors Teaching Students programme in June, alongside women with lived experience of ovarian cancer who generously shared their personal stories.

We are passionate about ensuring lived experience voices are at the forefront of change. By hearing directly from women affected by ovarian cancer, healthcare students gain a deeper understanding of the realities of diagnosis, treatment, and survivorship, knowledge that cannot be learned from textbooks alone.

The programme was well received, and for the women who choose to share their stories, the experience can be empowering. We hope these conversations stay with students throughout their careers and help shape more informed, compassionate decision-making in the future.





World Ovarian Cancer Day

For World Ovarian Cancer Day, we launched our campaign:

The symptoms can be easy to miss. The impact isn't.


The campaign focused on the often-overlooked reality that a cancer affecting a relatively small organ can have an enormous impact on a woman's body and life. Erin courageously shared her surgical scar, creating a powerful visual reminder of the scale of ovarian cancer treatment and its lasting effects.

The response was deeply moving. Women with ovarian cancer recognised their own experiences in Erin's story and shared how powerful it was to see that reality acknowledged publicly. For many members of the wider community, the image was confronting and surprising, helping them better



Would you know if you had ovarian cancer?

Learn the symptoms.
ovariancancerfoundation.org.nz/symptoms



The *symptoms* are easy to overlook.

The *impact* isn't.

WORLD OVARIAN CANCER DAY
ovariancancerfoundation.org.nz/wood

understand the significant impact ovarian cancer can have.

Symptom awareness in medical centres

In Ovarian Cancer Awareness Month we ran a Mediboard campaign, which placed ovarian cancer symptom messages directly into medical centres across New Zealand. We featured in 91 centres over three months.

By reaching women while they waited for appointments, the campaign aimed to help them recognise symptoms, take them seriously, and feel empowered to seek further investigation when something does not feel right. Medical centres also provided an opportunity to place these important messages in front of healthcare professionals, helping reinforce awareness of symptoms that can sometimes be dismissed as common or non-specific.

Through initiatives like these, we continue to raise awareness of ovarian cancer while ensuring the voices and experiences of women remain at the centre of the conversation.

Support Whakamārie

Ovarian cancer affects every aspect of a woman's life. Beyond treatment, many women face ongoing physical, emotional, and practical challenges.

Our support services aim to ensure women have access to information, connection, and care that helps them navigate life during and after diagnosis.

This year, 73 women received support through OCFNZ.

We developed and distributed new support brochures to raise awareness of OCFNZ's support services and ensure more women are able to access the support available to them at every stage of their journey.

Recognising the significant impact of treatment and surgery on the body, we continued to fund physiotherapy and rehabilitation through PINC & STEEL, with 30 women accessing this service. These services are not publicly funded, despite playing an important role in recovery and rebuilding strength and confidence after treatment.

Connection and peer-support remain a vital part of our work. We ran two online support sessions each month, with 24 women attending over the year, providing a safe space to share experiences and connect with others who understand.

We also funded one-on-one counselling for 19 women during the year. In November, we expanded this programme to include Rongoā Māori, ensuring women have access to a wider range of culturally grounded support options.

As demand continues to grow, we remain committed to ensuring no woman faces ovarian cancer alone.



“When my treatments finished, I had no confidence. I felt people were looking at me with pity. I was embarrassed—no hair, weak, ongoing symptoms. I was curled up like a ball of string. Imagine not having any support to unravel and get moving again. I so needed this support and direction.”



Ruby

We first met Ruby in 2024, when she shared her experiences with mucinous ovarian cancer and encouraged women to listen to their bodies to advocate for their health. Our relationship grew as she continued to show up for other women facing ovarian cancer, and on World Ovarian Cancer Day 2025 the talented musician gifted her song Dig Deeper to OCFNZ and the ovarian cancer community, a song born from hope, resilience, and her desire to walk alongside others on this road.

Later that year Ruby played a large role in shaping our State of Ovarian Cancer in Aotearoa Report. Her passion for change, for better outcomes for all women and a

brighter future for her children led her to share her thoughts boldly, bravely and with a huge heart.

Ruby had hoped to be at the launch of the report in person to use her voice for change, but sadly she passed away just days before the event, and her family held her funeral on the same day as our launch.

We missed her deeply and honoured her legacy by sharing her song and continuing the advocacy she cared so deeply about.

Our thoughts are with those closest to Ruby, her whānau, friends, and all who were part of her chosen family and community.

Show Up for Ovarian Cancer

Te Whakaputa mō te Mate Pukupuku Kākano-a-kōpu

In February, we hosted Show Up for Ovarian Cancer, to support those currently facing ovarian cancer, for those who will be diagnosed in the future, and to help raise vital funds to support our work.

From workplace fundraisers and community events to individual efforts and online support, 87 fundraisers came together to raise \$40,000. These funds help to strengthen our work across support, awareness, research and advocacy. Alongside fundraising, the campaign helped elevate conversations about ovarian cancer, encouraging greater awareness of symptoms and the importance of earlier understanding and recognition.

To everyone who hosted, donated, participated, or helped spread the word — thank you. Your support is helping ensure we can continue to show up for women and whānau affected by ovarian cancer across Aotearoa.

Street appeal

We tested the waters with our first-ever Street Appeal, showing up in Auckland, Tauranga and Oamaru. We started important conversations and raised funds, while connecting with communities. We look forward to expanding this approach in the future.

Bronwyn

\$3,000

Took on the Coast to Coast to push her own boundaries and remember her dear friend Wendy.

The Espejos

\$1,800

Spent 30 hours outside as a family to show support for their Mum, and other women who have faced a diagnosis.

Esther

\$7,000


Committed to 43 minutes of exercise each day to highlight the 43% five-year survival rate.



Rural Women New Zealand Region 4



The Espejos



Esther



Bronwyn - Coast to Coast



Soroptimist International of Aotearoa New Zealand



Bronwyn - Coast to Coast

LGSOC Initiative

He Mahi mā te te Mate Pukupuku
Kākano-a-kōpu kua puta paku noa

In April 2025 the FDA approved avutometinib and defactinib in recurrent low-grade serous ovarian cancer with KRAS mutations.

The application was made under the FDA accelerated approval pathway which allows an application to be considered and conditionally approved before all clinical trials are completed. This is the first-ever FDA-approved treatment specifically for LGSOC. A huge milestone that has come about thanks to the tireless advocacy of the LGSOC community around the world, and the tenacity of a growing community of LGSOC researchers that are committed to improving outcomes for all of us.

We were proud to support the second-ever LGSOC Awareness Day on 9 September and continue to be part of World Ovarian Cancer Day.

For LGSOC Awareness Day we were thrilled to host a webinar, presented by Dr Amanda Fader. Dr Fader shared a wealth of experience and knowledge with over 100 people tuning in from around the world.

For World Ovarian Cancer Day we were honored to receive continued support from media partners Silvercast Media and Piccadilly Lights and creative partner Topham Gurein.

With their support we were able to take LGSOC to the global stage and see women facing LGSOC featured on some of the most high profile billboard sites in the world at Piccadilly Circus and Times Square.

The biggest thanks has to go to the incredible women who fronted the campaign to share the message that while the symptoms may be easy to miss, the impact isn't.



Dr Amanda Fader
Obstetrician-Gynecologist



Scan to watch Dr Amanda Fader's informative talk



Canada (BC Cancer Foundation)

Funds raised: \$12,491

- Clinical trial advancement: Received approval through the Canadian Cancer Trials Group, in collaboration with the NRG Rare Tumor Committee, to proceed with a new randomized clinical trial comparing the targeted combination therapy avutometinib + defactinib versus standard chemotherapy for newly diagnosed low-grade serous ovarian cancer.
- National registry expansion: Secured continued support from Ovarian Cancer Canada to advance the national registry for rare gynecologic cancers, including low-grade serous carcinoma. Two registry-linked projects are underway, focused on clear cell and mucinous ovarian cancers.
- International research collaboration: Continued collaboration with Drs. Dane Cheasley and Kathleen Pishas (Australia) to evaluate novel drug combinations for the treatment of low-grade serous carcinoma. Additional testing is being planned across multiple laboratory model systems.
- Research publication support: Supported a recent peer-reviewed publication by Drs. Cheasley and Pishas demonstrating EGFR overexpression in LGSC tumors lacking other common molecular alterations (e.g., KRAS mutations).
- Hormonal therapy research: Continued efforts to better identify which LGSC tumors are most likely to respond to anti-estrogen therapies.

LGSOC Initiative

He Mahi mā te te Mate Pukupuku Kākano-a-kōpu kua puta paku noa

UK (University of Edinburgh)

Funds raised £57,922

Donations received through the LGSOC Initiative were used to fund part of the salary of a post-doctoral researcher (Dr Sarah Taylor). Sarah has optimised a protocol for routinely growing tumours derived from patient samples in the laboratory so that their responsiveness to various therapies can be tested outside of the patient. The team have expanded the number of LGSOC organoids in their library, and now have generated models from seven tumours. Sarah has also performed a drug screen to find cancer drugs which combine best with the drug trametinib, in the hope that we can test these combinations in clinical trials. A number of drug hits have been identified and validated, and these drug combinations may represent novel therapeutic strategies to improve response rates, particularly in trametinib resistant tumours. A number of these hit drugs have also been validated in the organoid models. This work has been presented at the Organoids Are Us conference, raising the profile of LGSOC research and LGSOC Initiative. The funding has also supported the development of students in the lab, two undergraduate students and one masters student contributing to LGSOC projects under Sarah's supervision during the year.

US (STAAR)

\$1,200 (direct donations, fundraisers not tracked)

STAAR Low-Grade Serous Ovarian Cancer Foundation focus on funding pioneering studies that seek to understand, treat, and ultimately cure this rare and challenging disease. Recent funding has focused on multi-year studies. They are currently funding:

Dr K.K. Wong

MD Anderson Cancer Centre
Analysis of full-length transcripts in low-grade serous ovarian cancer by long-read sequencing
Dr. Wong is using advanced genetic sequencing to better understand how LGSOC tumors function and why patients may respond differently to treatment—laying the groundwork for more precise, personalized therapies in the future.

Dr H. Kenny

University of Chicago
A High-Throughput Screening Program to Discover Combinatorial Treatments Targeting Low-Grade Serous Ovarian Cancer
Dr. Kenny is studying LGSOC in a three-dimensional lab model that closely mimics real tumors, helping researchers identify treatments that are more effective, better tolerated, and more relevant for patients.

OCFNZ

In New Zealand, OCFNZ funded \$1,100 to support a PhD student to undertake a project on LGSOC. Megan Lilly is undertaking postgraduate research which uses collaboratively-obtained laboratory models of LGSOC to identify whether targeted therapies known to be effective in other cancers can be repurposed for LGSOC, based on predictions from state-of-the-art LGSOC tumour profiling.

"I'm driven to study LGSOC as it tends to affect women from a younger age and is underrepresented in research" says Megan.

We also provided \$20,000 of funding to Associate Professor Heather Cunliffe, to support her work looking for new and more effective treatment options for women with low-grade serous ovarian cancer, which could then be tested in future international clinical trials.

OCFNZ funded two international travel grants, which provides funding so an early career researcher can visit an international laboratory. This visit will facilitate stronger global cooperation, and expose researchers to new ideas and techniques that they can bring

back to Aotearoa. Both recipients will visit world-leading LGSOC labs, further enhancing global capability in this area.

Rosa Latton of the University of Otago, will spend time in Dr Robb Hollis' lab to explore profiling and genotypic analysis of low-grade serous ovarian cancer. Katie Walker, also of the University of Otago will be travelling to Australia to work with researcher Dr Anna DeFazio.

Katie says "My passion for ovarian cancer research is driven by the need for better health outcomes for women affected by ovarian cancer, from understanding risk, to improved diagnosis and treatment. The opportunity to be immersed in a world-leading ovarian cancer research team will enhance my skills and knowledge as an effective and translational researcher here in Aotearoa."

"I'm excited to have the opportunity to uncover new therapeutic targets so we can develop effective treatment plans for these patients"

- Megan Lilly, University of Otago



Advisory committees

Ngā komiti kaupapa

People who have faced ovarian cancer tell us that they often feel invisible. That their cancer and their journey feels silent in many ways.

Wāhine with lived experience of ovarian cancer have powerful voices that need to be heard. Ensuring that our work reflects the wants and needs of women and whānau that are facing ovarian cancer has always been central to OCFNZ. In December we formalised this unwavering commitment by establishing two lived experience advisory committees.



Meet the committee members

Lived Experience Advisory Committee

Pae Kōrero Wāhine kua Tūrora
Made up of five women who have an ovarian cancer diagnosis.



Chloe Adams



Erin Bassett



Lisa Finucane



Sarah Luxon



Jennifer Thomson

Whānau Lived Experience Advisory Committee

Pae Kōrero-ā-Whānau ā ngā Wāhine kua Tūrora
Made up of five partners and parents of women who are facing or have passed away from ovarian cancer.



Kent Favel



Bruce Knox



Ele Ludemann



Malcolm MacLeod



Mark Scott

“ Being a part of the Lived Experience Advisory Committee has been an incredibly meaningful way to push for real change in New Zealand's ovarian cancer support. In a field that has so often been voiceless, giving a voice to the people who are living it means that we can move the needle on care, treatment and advocacy to better match the realities of ovarian cancer. We get to make a bit of good out of something so horrible. ”

- Chloe Adams, Advisory Committee

A message from our Founder and Chair

He kōrero nā tō mātou Kaiwhakapoupoua, Tiamana hoki

The past twelve months have been a time of unprecedented challenge and achievement for OCFNZ.

With the resignation of our previous GM, we started the financial year with just one part-time employee. It is a credit to our Engagement and Support Coordinator Holly Townsend, and OCFNZ's Trustees that the organisation continued to not just function, but grow during this time.

In June, after a competitive recruitment process we were pleased to welcome our new General Manager Liz Pennington. Liz's involvement with OCFNZ began in 2020 as a volunteer, before joining the board as a trustee in 2021. She brings a valuable background in trauma counselling, nursing and non-profit leadership, and a strong commitment to center the voices of lived experience in our work.

In the past twelve months OCFNZ has supported more women than ever before, launched our powerful State of Ovarian Cancer report at parliament, built ovarian cancer awareness and continued to be recognised as an international leader for low-grade serous ovarian cancer. But if there is one thing that signifies the past twelve months for OCFNZ, it is research.

Despite being the least survivable women's cancer, ovarian cancer is also one of the least researched cancers - not only in New Zealand, but also globally. Research is crucial to improving outcomes, and as one of the main sources of ovarian cancer research funding within NZ, what we do matters. In the past twelve months we've funded a variety of important science across multiple ovarian cancer types, including our largest competitive research grant to date. We're also helping develop the research sector, leveraging connections built through our LGSOC Initiative to provide early career ovarian cancer researchers with placements with international experts, to learn new skills and bring them home to NZ. And multiple women with hard to treat rare ovarian cancers have been able to access tumour testing to guide treatment discussions thanks to our support of places on a rare cancer trial which could change future medical practice.

Looking forward to how we can build on this momentum in the future, we formalised a new partnership with the Ovarian Cancer Research Foundation in Australia, to bring their successful

ovarian cancer research fundraising campaign Frocktober to New Zealand. In combination with a successful Long Lunch held in Auckland - OCFNZ raised over \$240,000 gross at these events, which means that next year we will be able to support more research advances than ever before.

For women diagnosed with ovarian cancer and their family and friends, we acknowledge the challenges remain immense. As a small organisation OCFNZ has been able to

have a disproportionate impact in this space because of the passion and commitment of our supporters, volunteers, trustees and staff. As we end the year stronger than we began, we continue to work towards a future where ovarian cancer is known, women feel supported, systemic barriers are broken down, and scientific discoveries transform survival.

Women deserve nothing less.

Thank you for being part of this journey.



Jane Ludemann
Founder

Tō mātou Kaiwhakapoupoua



Alana Allan
Chairperson

Tiamana Poari

Thank you Ngā mihi

On occasion, we rely on the support of volunteers and pro bono services to help us with various projects. Thank you to everyone who has supported the Ovarian Cancer Foundation New Zealand this year.

Annie McDonald
Bronwyn Harris
Bronwyn Trewain
Bruce Knox
Candice Kitt
Carol Nelson
Carolyn Rohm
Chloe Adams
College of Nurses Aotearoa
Dr Cecile Bergzoll
Dr Cherie Blenkiron
Dr Heather Cunliffe
Dr Michelle Vaughan
Dr Michelle Wilson
Ele and Grant Ludemann
Erin and Chris Bassett
Gallaway Cook Allan
GoMedia
Harvey Green Wyatt
Chartered Accountants
Honest Wolf
Jennifer Thomson
Kate Weston
Kent Favel
Leondra Roberts
Lion Foundation
Lisa Finucane
Liz Mitchell
Malcolm and Sara MacLeod
Mark Scott

Marie S
Mitchell Carlyle
National Distillery Company
PINK & STEEL
Rotary Club of Oamaru
Ruby and Taylor Smith
Sarah Luxon
Sarah Palmer
Selwyn's Lions Club
Shar Sutherland Todd
Sorooptimists International of
Aotearoa New Zealand
Stella Coleman
TELUS Health
The Fundraising Agency
Topham Gurein
Whitney Gernhoefer
Zani Polson
Our generous long lunch donors
Our amazing fundraisers
Our incredible ovarian cancer
community

Funders

AstraZeneca
Grassroots Trust
Lottery Community
Pub Charity
GSK

We would also like to acknowledge the support of our global low-grade serous community and thank those people and organisations who have supported us with various activities this year.

Alex Coppock-Bunce
Alisa M
ANZGOG
BC Cancer Foundation
Brianna Leigh Wagner
Diane Evans
Dr David Gershensen
Elsa Larsen
Jasmine Rose
Kari Neumeyer
Leslie Vreeland-Corpe
Liz Miller
Michelle Hill
Rachel Sackett
Silvercast Media
STAAR Ovarian Cancer
University of Edinburgh
Verastem
Victoria Dyson-Lynne



Financial report

Te Rīpoata Pūtea

Ovarian Cancer
Foundation NZ

For the year ended
31 March 2026

Prepared by
Harvie Green Wyatt

Approval of financial report

Ovarian Cancer Foundation NZ
For the year ended 31 March 2026

The Trustees are pleased to present the approved financial report including the historical financial statements of Ovarian Cancer Foundation NZ for year ended 31 March 2026.

APPROVED

Alana Allan

Alana Allan

Chairperson
02 August 2026

Malcolm MacLeod

Malcolm MacLeod

Treasurer
31 July 2026

Compilation information

Ovarian Cancer Foundation NZ For the year ended 31 March 2026

Compilation Report to the Trustees of Ovarian Cancer Foundation New Zealand.

Scope

On the basis of information provided by you we have complied, in accordance with Service Engagement Standard No.2-Compilation of Financial Information, the special purpose financial statements of Ovarian Cancer Foundation New Zealand for the year ended 31 March 2026.

These statements have been prepared on the basis disclosed in the statement of accounting policies and notes to the financial Statements.

Responsibilities

You have determined that the basis upon which the financial statements have been prepared is appropriate to meet your needs and for the purpose that the financial statements were prepared. The Trustees are solely responsible for the information contained in the special purpose financial statements and have determined that the financial reporting framework used is appropriate to meet your needs and for the purpose that the special purpose financial statements were prepared.

The financial statements were prepared exclusively for your benefit. Neither HGW Limited, nor any of our employees, directors, agents, or related entities shall have any responsibility or liability to any other person on any grounds whatsoever, including without limitation liability in negligence, for the contents of the special purpose financial statements.

No Audit or Review Engagement Undertaken

Our procedures use accounting expertise to undertake the compilation of the financial statements from information which you provided. A compilation is limited primarily to the collection, classification, and summarisation of financial information. Our procedures do not include verification or validation procedures of the information and are not intended to detect any errors or fraud present in or inferable from the information you have provided us. No audit or review engagement has been performed, and accordingly no assurance is expressed. If you are concerned about errors or fraud in the information you provide to us, please let us know and we can discuss changing the scope of our work with you.

Disclaimer

As mentioned earlier in these terms, we have compiled the financial statements based on information provided to us which has not been subject to an audit or review engagement. Accordingly, neither HGW Limited, nor any of our employees, directors, agents, or related entities shall be responsible for nor liable in relation to the reliability, accuracy, or completeness of the compiled financial information. You agree that you shall not bring any claim or demand nor take any action or institute any proceeding against HGW, its employees, directors, agents, or related entities in respect of any loss caused or suffered by you due to your reliance on the compiled financial information.



Harvie Green Wyatt
Level 5, 229 Moray Place
Dunedin 9016
Dated: 31 July 2026

Entity information

Ovarian Cancer Foundation New Zealand For the year ended 31 March 2026

'Who are we?', 'Why do we exist?'

Legal Name of Entity

Ovarian Cancer Foundation New Zealand

Entity Type and Legal Basis

The Trust was registered as a Charitable Trust under the Charitable Trusts Act 1957 on 14th June 2018. The Trust was also registered with the Department of Internal Affairs Services as a Charity on 31st July 2018.

Registration

Charitable Trusts Act Registration Number 2707031
DIA Charities Services Registration Number CC55925
Registration Date 31/07/2018

Entity's Purpose or Mission

Ovarian Cancer Foundation NZ's purpose is to improve ovarian cancer care in New Zealand by funding transformational research, advocating with women for equitable care, facilitating support for women and raising awareness of ovarian cancer. To honour the initial purpose of the organisation we retain a special interest in low-grade serous ovarian cancer through our activities.

Entity Structure

The Trust operates from Dunedin. The Trust Deed states that there must be between two and eight trustees. The Trust currently has seven trustees that constitute the governance board. The existing Trustees have power to appoint further Trustees from members of the public who have an interest in the Trust's charitable purpose.

Main Sources of Entity's Cash and Resources

The Trust raises all its funds by way of donations and fundraising from the community and by grants from organisations. All money we receive covers the cost of our services (research, advocacy, support and awareness) as well as our operating costs (general, marketing, fundraising etc).

Entity's Governance Arrangements

Key decisions for our charity are made by a Board of Trustees. They set the strategic direction, ensure financial stability and oversee its overall operations.

Other Entities Controlled by the Entity

None.

Main Methods Used by Entity to Raise Funds

Donations

Donations are received from a variety of sources including:

- Through our website
- Directly from individuals, community groups and businesses
- Fundraising events
- Grants

Fundraising

Members of our community fundraise on our behalf through a number of fundraising initiatives.

Promotion

Our team and trustees engage with the community through presentations, and we promote our work through social media, our website ovariancancerfoundation.org.nz and lgsoc.org along with public facing campaigns.

Entity’s Reliance on Volunteers and Donated Goods or Services

The Ovarian Cancer Foundation NZ (OCFNZ) currently has approximately 30 volunteers contributing across governance, lived experience advocacy, and medical/scientific advisory roles. These volunteers include women with lived experience of ovarian cancer, whānau, clinicians, researchers, and leaders who collectively help shape the organisation’s advocacy, support services, awareness activity, and strategic direction.

The contribution of these volunteers whose time invested ranges from weekly to monthly, is fundamental to the organisation’s ability to achieve its mission. They bring invaluable lived experience, clinical expertise, governance leadership and professional knowledge that ensures the organisation’s work remains credible, relevant, evidence informed and centred on the needs of those affected by ovarian cancer.

Postal Address

C/- Gallaway Cook Allan, P O Box 143, Dunedin Central, Dunedin 9054

This statement has been prepared without conducting an audit or review engagement, and should be read in conjunction with the accounting policies and notes to the Performance Report.

Statement of service performance

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2026

'What did we do?', 'When did we do it?'

Activity	This Year	Last Year	
Ovarian Cancer Awareness Month	Reach -600,000 Visits to website -4,000 Mediboard screens -91	Reach -365,000 Visits to website -3,415 Mediboard screens -83	
Group Support Sessions Delivered	24	24	
Funded Counselling Services	25	9	
Advisory Groups Formed	-Lived Experience -Whanau -Medical and Scientific Advisory Panel	Nil	
Physiotherapy & Rehabilitation Sessions	30 women supported 60 sessions funded	31 women supported 62 sessions funded	
Research Grants and Activities		\$129,483	\$23,534
National Surveys Undertaken	3	Nil	
Report Released in Parliament	1	Nil	
Travel Grants Awarded		\$20,042	\$8,766
Professional Development Grants Awarded		\$5,364	Nil
Bequests		\$5,000	\$10,000
Fundraising Campaigns Run	2	1	
Events	1	0	
Employees	3	2	

Statement of financial performance

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2026

'How was it funded?', 'What did it cost?'

	NOTES	2026	2025
Revenue			
General Grants	1	74,960	57,506
Non-government service delivery, grants/contracts	1	34,671	25,876
Donations, koha, bequests and other general fundraising activities	1	577,505	360,464
Other revenue	1	298	-
Interest, dividends and other investment revenue	1	18,628	-
Total Revenue		706,061	443,846
Expenses			
Expenses related to public fundraising	2	165,716	64,078
Employee remuneration and other related expenses	2	216,205	172,553
Other expenses related to service delivery	2	177,141	78,012
Grants and Donations made	2	138,405	37,475
Other expenses	2	2,950	614
Total Expenses		700,417	352,733
Surplus/(Deficit) for the Year		5,644	91,113

Statement of financial position

Ovarian Cancer Foundation New Zealand
As at 31 March 2026

'What the entity owns?' and 'What the entity owes?'

	NOTES	31 MAR 2026	31 MAR 2025
Assets			
Current Assets			
Cash and short-term deposits	3	191,635	645,779
Debtors and prepayments	3	27,671	-
Total Current Assets		219,306	645,779
Non-Current Assets			
Property, Plant and Equipment	5	3,679	614
Investments	3	455,250	-
Total Non-Current Assets		458,929	614
Total Assets		678,234	646,393
Liabilities			
Current Liabilities			
Creditors and accrued expenses	4	17,783	-
Employee costs payable	4	8,415	-
Deferred revenue	4	25,000	25,000
Total Current Liabilities		51,198	25,000
Total Liabilities		51,198	25,000
Total Assets less Total Liabilities (Net Assets)		627,036	621,393
Accumulated Funds			
Accumulated surpluses or (deficits)	6	484,867	479,224
Reserves	6	142,169	142,169
Total Accumulated Funds		627,036	621,393

Statement of cash flows

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2026

'How the entity has received and used cash'

	2026	2025
Cash Flows from Operating Activities		
Cash received		
Donations, fundraising and other similar receipts	581,145	350,836
General grants	74,960	57,506
Non-government service delivery grants/contracts	30,520	25,876
Interest, dividends and other investment receipts	14,438	-
Other cash received	298	-
Total Cash received	701,361	434,217
Cash Payments		
Payments related to public fundraising	(71,962)	(35,210)
Employee remuneration and other related payments	(208,203)	(172,553)
Other payments related to service delivery	(261,438)	(106,881)
Grants and donations paid	(152,617)	(37,475)
GST	(20)	-
Total Cash Payments	(694,240)	(352,119)
Total Cash Flows from Operating Activities	7,121	82,099
Cash Flows from Investing and Financing Activities		
Receipts from sale or maturity of investments	495,251	-
Payments to acquire property, plant and equipment	(6,014)	-
Payments to purchase investments	(950,501)	-
Total Cash Flows from Investing and Financing Activities	(461,264)	-
Net Increase/(Decrease) in Cash	(454,144)	82,099
Bank Accounts and Cash		
Opening cash	645,779	563,680
Closing cash	191,635	645,779
Net change in cash for period	(454,144)	82,099

Statement of accounting policies

Ovarian Cancer Foundation New Zealand
As at 31 March 2026

'How did we do our accounting?'

Basis of Preparation

This Performance Report is prepared in accordance with the XRB’s Tier 3 (NFP) Standard. The entity is eligible to apply these requirements as it does not have public accountability and has total annual expenses of less than \$5,000,000. All transactions in the Performance Report are reported using the accrual basis of accounting. This Performance Report is prepared under the assumption that the entity will continue to operate for the foreseeable future.

The Performance Report is presented in New Zealand dollars.

Goods and Services Tax (GST)

The entity was registered for GST from 1 February 2026. Therefore all amounts before 31 January 2026 are stated inclusive of GST (if any), and all amounts after 1 February 2026 are stated exclusive of GST (if any).

Income Tax

Ovarian Cancer Foundation NZ is wholly exempt from New Zealand income tax having fully complied with all statutory conditions for these exemptions.

Bank Accounts and Cash

Bank accounts and cash in the Statement of Cash Flows comprise cash balances and bank balances (including short term deposits) with original maturities of 90 days or less.

Changes in Accounting Policies

There have been no changes in accounting policies. Policies have been applied on a consistent basis with those of the previous reporting period.

Notes to the performance report

Ovarian Cancer Foundation New Zealand For the year ended 31 March 2026

	2026	2025
1. Analysis of Revenue		
General Grants		
Grants	74,960	57,506
Total General Grants	74,960	57,506
Non-government service delivery, grants / contracts		
Corporate Revenue & Pships	4,151	-
Funding Applications	30,520	25,876
Total Non-government service delivery, grants / contracts	34,671	25,876
Donations, koha, bequests and other general fundraising activities		
Donations and fundraising		
Fundraising	381,685	160,016
Donations	74,820	64,297
Major Gifts	116,000	125,000
New Zealand (Bequests)	5,000	11,152
Total Donations, koha, bequests and other general fundraising activities	577,505	360,464
Other revenue		
Other Income	298	-
Total Other revenue	298	-
Interest, dividends and other investment revenue		
Interest Income	18,628	-
Total Interest, dividends and other investment revenue	18,628	-
	2026	2025

2. Analysis of Expenses

Expenses related to public fundraising		
Fundraising	54,905	20,701
Marketing	16,938	9,494
Website	2,149	5,015
Fundraising Costs	91,723	28,868
Total Expenses related to public fundraising	165,716	64,078
Employee remuneration and other related expenses		
HR	1,217	-
Training & Development	8,075	120
Travel -National	6,375	1,365
Wages	200,537	171,069
Total Employee remuneration and other related expenses	216,205	172,553

	2026	2025
Other expenses related to service delivery		
Advocacy, awareness and support		
Advocacy	47,492	4,788
Awareness	43,124	15,365
Support	21,711	19,572
LGSOC Initiative	18,997	11,441
Total Advocacy, awareness and support	131,324	51,165
Administrative & Operating Costs		
Bank Fees	199	78
General Expenses	2,745	179
Consulting, Legal & Reporting	14,703	2,639
Gifts -Internal	-	352
Insurance	2,270	1,507
Office Expenses	6,635	7,145
Payment Processing Fees	17,464	13,364
Telephone & Internet	1,800	1,584
Total Administrative & Operating Costs	45,817	26,847
Total Other expenses related to service delivery	177,141	78,012
Grants and Donations made		
Research Activities	138,405	37,475
Total Grants and Donations made	138,405	37,475
Other expenses		
Depreciation	2,950	614
Total Other expenses	2,950	614
	2026	2025

3. Analysis of Assets

Cash and short-term deposits		
OCFNZ -Operating Account	133,684	644,565
Stripe -Payment Processing Account	2,712	1,076
OCFNZ -Savings Account	83	-
OCFNZ -Credit Card (Whitney)	-	137
OCFNZ Credit Card -Liz	5,156	-
Term Deposit #80	50,000	-
Total Cash and short-term deposits	191,635	645,779
Debtors and prepayments		
Accrued Interest	4,190	-
GST	22,248	-
Accounts Receivable	1,232	-
Total Debtors and prepayments	27,671	-

	2026	2025
Investments		
Term Deposit #77	50,000	-
Term Deposit #78	160,000	-
Term Deposit #79	145,250	-
Term Deposit #81	100,000	-
Total Investments	455,250	-
	2026	2025

4. Analysis of Liabilities

Creditors and accrued expenses		
Accounts Payable	17,783	-
Total Creditors and accrued expenses	17,783	-
Employee costs payable		
Provision for Annual Leave	8,415	-
Total Employee costs payable	8,415	-
Deferred revenue		
Grants In Advance	25,000	25,000
Total Deferred revenue	25,000	25,000
	2026	2025

5. Plant & Equipment

Office Equipment		
Opening carrying amount	614	1,228
Additions	6,014	-
Depreciation	(2,949)	(614)
Total Office Equipment	3,679	614
Total Plant & Equipment	3,679	614
	2026	2025

6. Accumulated Funds

Accumulated Funds		
Opening Balance	479,224	388,111
Accumulated surpluses or (deficits)		
Current year earnings	5,644	91,113
Total Accumulated surpluses or (deficits)	5,644	91,113
Total Accumulated Funds	484,867	479,224
Restricted or Discretionary Reserves		
Opening Balance	142,169	142,169
Total Restricted or Discretionary Reserves	142,169	142,169
Total Accumulated Funds	627,036	621,393

	2026	2025
--	------	------

\$142,169 is being held with the intention of bringing a low-grade serous ovarian cancer clinical trial to New Zealand, when a suitable trial becomes available. This is in keeping with the purpose for which it was raised.

7. Commitments

There are no commitments as at 31 March 2026 (Last year -nil).

8. Contingent Liabilities and Guarantees

There are no contingent liabilities or guarantees as at 31 March 2026 (Last year -nil).

	2026	2025
9. Related Parties		
Donations Received		
Trustees and close family members -Donations	129,980	122,754
Total Donations Received	129,980	122,754

The Founder provides services to the Trust at no charge equatable to 0.15 FTE position.
The Trustees provide their skills and oversight of the Trust at no charge.

The Ludemann family have agreed to donate \$115,000 per annum to support the trust in its administration and payroll expenditure up until 31 March 2026.

10. Deferred Revenue

Description	Purpose and nature of the documented expectations over future use	Date	Original amount \$	Current year \$	Last year \$
Wages	Grant received for the payment of wages in the next financial year. The funds can not be used for any other purpose.	9 March 2026	\$25,000.00	\$25,000.00	\$25,000.00

11. Events After the Balance Date

There were no events that have occurred after the balance date that would have a material impact on the Performance Report (Last year -nil).

Depreciation schedule

Ovarian Cancer Foundation New Zealand
For the year ended 31 March 2026

	COST	OPENING VALUE	PURCHASES	SALE PRICE	CAPITAL GAIN	DEP RECOVERED	LOSS	RATE	METHOD	DEPRECIATION	CLOSING ACCUM DEP	CLOSING VALUE
Office Equipment												
Merchant Link -Tap & Go Devices x 4	1,861	-	1,861	-	-	-	-	50%	DV	620	620	1,240
Dell Inspiron 16" Laptop	1,404	307	-	-	-	-	-	50%	DV	154	1,250	154
Dell Inspiron 16" Laptop	1,404	307	-	-	-	-	-	50%	DV	154	1,250	154
Dell Pro 16" Business Laptop (Admin)	1,995	-	1,995	-	-	-	-	50%	DV	997	997	997
Dell Pro 16" Business Laptop (GM)	2,029	-	2,029	-	-	-	-	50%	DV	1,014	1,014	1,014
Merchant Link -Tap & Go Devices -setup cost	130	-	130	-	-	-	-	50%	DV	11	11	119
Total Office Equipment	8,822	614	6,014	-	-	-	-			2,950	5,144	3,679
Total	8,822	614	6,014	-	-	-	-			2,950	5,144	3,679



ovariancancerfoundation.org.nz



office@ocfnz.org.nz



[/ovariancancerfoundationnz](https://www.facebook.com/ovariancancerfoundationnz)



[/ovariancancerfoundationnz](https://www.instagram.com/ovariancancerfoundationnz)



[/Ovarian Cancer Foundation New Zealand](https://www.linkedin.com/company/Ovarian-Cancer-Foundation-New-Zealand)



**Ovarian Cancer
Foundation NZ**

Te Kaikōkiri Mate Pukupuku Kākano-ā-Kopu ki Aotearoa